Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-28T09:55:32.724Z Has data issue: false hasContentIssue false
  • English
  • Français

The Science of Antipsychotics: Mechanistic Insight

Published online by Cambridge University Press:  07 November 2014

Carol A. Tamminga
Get access Rights & Permissions [Opens in a new window]

Abstract

With the introduction of conventional antipsychotics in the 1950s, clinicians began to expect effective treatment of positive symptoms of schizophrenia. However, these drugs do not resolve negative and cognitive symptoms of schizophrenia and are also associated with serious side effects, including extrapyramidal side effects (EPS) and tardive dyskinesia. In 1989, clozapine was introduced and labeled the first new antipsychotic owing to its improved efficacy and side-effect profile. Clozapine proved effective in alleviating many of the positive, negative, and cognitive symptoms of schizophrenia, without causing inevitable EPS or tardive dyskinesia. Over the past decade, a number of different new antipsychotics have been developed. These drugs have an affinity for multiple dopamine-receptor subtypes as well as serotonin, norepinephrine, and glutamate receptors, allowing for better treatment outcomes. The antagonism of the 5-HT2A receptor may be responsible for improvement in negative symptoms and decrease in EPS. In addition to providing enhanced efficacy, the affinity of the new drugs for multiple receptors introduces new side effects not seen with the conventional agents, including weight gain. Each new antipsychotic has a unique receptor-binding profile that corresponds to its pharmacologic and side-effect profile. Understanding the differences in mechanisms of action of new antipsychotics will allow physicians to better choose treatment that meets the needs of each individual patient.

Type
Academic Supplement
Information
CNS Spectrums , Volume 8 , supplement S2: Optimizing Treatment for Patients With Schizophrenia: Targeting Positive Outcomes , November 2003 , pp. 5 - 9
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Medalia, A, Gold, JM, Merriam, A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol. 1988;3:249–271.CrossRefGoogle ScholarPubMed
2.Kane, J, Mayerhoff, D. Do negative symptoms respond to pharmacological treatment? Br J Psychiatry. 1989;55(suppl 7):115–118.CrossRefGoogle Scholar
3.Tollefson, GD, Sanger, TM, Lu, Y, Thieme, ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry. 1998;55:250–258.CrossRefGoogle ScholarPubMed
4.Casey, DE. Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr Scand Suppl. 1994;380:14–20.CrossRefGoogle ScholarPubMed
5.Tandon, R, Jibson, MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology. 2003;28(suppl 1):9–26.CrossRefGoogle ScholarPubMed
6.Seeman, P, Lee, T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975;188:1217–1219.CrossRefGoogle ScholarPubMed
7.Creese, I, Burt, DR, Snyder, SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192:481–483.CrossRefGoogle ScholarPubMed
8.Holcomb, HH, Cascella, NG, Thaker, GK, Medoff, DR, Dannals, RF, Tamminga, CA. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry. 1996;153:41–49.Google ScholarPubMed
9.Meltzer, HY, Matsubara, S, Lee, JC. The ratios of serotonin2 and dopamine2, affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989;25:390–392.Google ScholarPubMed
10.Zorn, SH, Lebel, LA, Schmidt, AW, et al.Pharmacological and neurochemical studies with the new antipsychotic ziprasidone. In: Palomo, T, Benninger, RJ, Archer, T, eds. Interactive Monoaminergic Disorders. Madrid, Spain: Editorial Sintesis; 1999:377–393.Google Scholar
11.Schmidt, AW, Lebel, LA, Howard, HR Jr, Zorn, SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197–201.CrossRefGoogle ScholarPubMed
12.Breier, AF, Malhotra, AK, Su, TP, et al.Clozapine and risperidone in chronic schizophrenia: effects on symptoms, Parkinsonian side effects, and neuroendocrine responses. Am J Psychiatry. 1999;156:294–298.CrossRefGoogle Scholar
13.Conley, RR, Tamminga, CA, Bartko, JJ, et al.Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998;155:914–920.CrossRefGoogle ScholarPubMed
14.Wirshing, DA, Marshall, BD Jr, Green, MF, Mintz, J, Marder, SR, Wirshing, WC. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry. 1999;156:1374–1379.CrossRefGoogle ScholarPubMed
15.Lahti, AC, Holcomb, HH, Weiler, MA, Medoff, DR, Tamminga, CA. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol Psychiatry. 2003;53:601–608.CrossRefGoogle ScholarPubMed
16.Holcomb, HH, Lahti, AC, Medoff, DR, Weiler, M, Dannals, RF, Tamminga, CA. Brain activation patterns in schizophrenic and comparison volunteers during a matched-performance auditory recognition task. Am J Psychiatry. 2000;157:1634–1645.CrossRefGoogle ScholarPubMed
17.Jarvis, MF, Murphy, DE, Williams, M. Quantitative autoradiographic localization of NMDA receptors in rat brain using [3H]CPP: comparison with [3H]TCP binding sites. Eur J Pharmacol. 1987;141:149–152.CrossRefGoogle ScholarPubMed
18.Javitt, DC, Zukin, SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301–1308.Google ScholarPubMed
19.Itil, T, Keskiner, A, Kiremitci, N, Holden, JM. Effect of phencyclidine in chronic schizophrenics. Can Psychiatr Assoc J. 1967;12:209–212.CrossRefGoogle ScholarPubMed
20.Bakshi, VP, Geyer, MA. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology (Berl). 1995;122:198–201.CrossRefGoogle ScholarPubMed
21.Burris, KD, Molski, TF, Xu, C, et al.Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381–389.CrossRefGoogle ScholarPubMed
22.Tamminga, CA, Carlsson, A. Partial dopamine agonists and dopaminergic stabilizers in the treatment of psychosis. Curr Drug Target CNS Neurol Disord. 2002;1:141–147.CrossRefGoogle ScholarPubMed
23.Jordan, S, Koprivica, V, Chen, R, Tottori, K, Kikuchi, T, Altar, CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137–140.CrossRefGoogle ScholarPubMed
24.Friedman, JI, Temporini, H, Davis, KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry. 1999;45:1–16.CrossRefGoogle ScholarPubMed
25.Heresco-Levy, U. N-Methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade. Int J Neuropsychopharmacol. 2000;3:243–258.CrossRefGoogle ScholarPubMed
26.Hosak, L, Libiger, J. Antiepileptic drugs in schizophrenia: a review. Eur Psychiatry. 2002;17:371–378.CrossRefGoogle ScholarPubMed
27.Kane, JM, Carson, WH, Saha, AR, et al.Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763–771.CrossRefGoogle ScholarPubMed